La neurosonologia. Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative. Nelle patologie degenerative e vascolari cerebrali

Similar documents
Transcranial sonography in movement disorders

Learnings from Parkinson s disease: Critical role of Biomarkers in successful drug development

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

The contribution of transcranial sonographic examination to the diagnosis of Parkinson s disease

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

FDG-PET e parkinsonismi

ORIGINAL CONTRIBUTION. Transcranial Brain Sonography Findings in Discriminating Between Parkinsonism and Idiopathic Parkinson Disease

The Parkinson s You Can t See

Evaluation of Parkinson s Patients and Primary Care Providers

Differential Diagnosis of Hypokinetic Movement Disorders

Early Clinical Features of Parkinson s Disease and Related Disorders. Dr. Alastair Noyce

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci.

Imaging biomarkers for Parkinson s disease

! slow, progressive, permanent loss of neurologic function.

Pietro Cortelli. IRCCS Istituto delle Scienze Neurologiche di Bologna DIBINEM, Alma Mater Studiorum - Università di Bologna

Update on functional brain imaging in Movement Disorders

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota

MOVEMENT DISORDERS AND DEMENTIA

III./3.1. Movement disorders with akinetic rigid symptoms

Neuropathology of Neurodegenerative Disorders Prof. Jillian Kril

Non Alzheimer Dementias

Atypical parkinsonism

Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

The Latest Research in Parkinson s Disease. Lawrence Elmer, MD, PhD Professor, Dept. of Neurology University of Toledo

Case Report Hyperechogenicity of the Substantia Nigra in Parkinson s Disease: Insights from Two Brothers with Markedly Different Disease Durations

L ecografia cerebrale: accuratezza diagnostica Dr Patrizio Prati Neurologia CIDIMU Torino

Dementia and Healthy Ageing : is the pathology any different?

Dementia: It s Not Always Alzheimer s

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

I do not have any disclosures

Parkinson s Disease Update

Common Forms of Dementia Handout Package

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia

Non-motor symptoms as a marker of. Michael Samuel

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences

Comprehensive Approach to DLB Management

DOWNLOAD PDF DOPAMINERGIC IMAGING IN PARKINSONS DISEASE : SPECT CHRISTOPH SCHERFLER AND WERNER POEWE

Biomedical Technology Research Center 2011 Workshop San Francisco, CA

Dementia: A Comprehensive Update Neuroimaging, CSF, and genetic biomarkers in dementia

UPDATE ON RESEARCH IN PARKINSON S DISEASE

Neuro degenerative PET image from FDG, amyloid to Tau

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

brain MRI for neuropsychiatrists: what do you need to know

United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline

Redefinition of Parkinson s Disease

Cheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy

Clinical Features and Treatment of Parkinson s Disease

Parkinson s UK Brain Bank

Prodromal and Early Parkinson s Disease Diagnosis

Objectives. Distinguishing Parkinson s disease from other parkinsonian and tremor syndromes. Characteristics. Basal Ganglia Structures

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient

P20.2. Characteristics of different types of dementia and challenges for the clinician

Basal ganglia motor circuit

2016 Programs & Information

Emerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018

Hypokinetic Movement Disorders

DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD

Il ruolo di nuove tecniche di imaging per la diagnosi precoce di demenza

Clinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor

The ABCs of Dementia Diagnosis

Moving Treatment Earlier Disease Modification in Early PD

A Parkinson s Disease and related disorders

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia

Change the size of any window by dragging the lower left corner. Use controls

Dr Barry Snow. Neurologist Auckland District Health Board

Revised criteria for the clinical diagnosis of dementia with Lewy. Dementia with Lewy bodies. (Dementia with Lewy Bodies)

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

Form D1: Clinician Diagnosis

Movement Disorders: A Brief Overview

CAREGIVER SUMMIT. The PD You Can't See: Dealing with Non-Motor Symptoms. Kaitlyn Roland, PhD. Sponsored by:

AGED SPECIFIC ASSESSMENT TOOLS. Anna Ciotta Senior Clinical Neuropsychologist Peninsula Mental Health Services

Extrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010

White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration

Introduction to Dementia: Diagnosis & Evaluation. Created in March 2005 Duration: about 15 minutes

Parkinson disease (PD) is a progressive neurodegenerative disorder. Transcranial Sonography of the Substantia Nigra: Digital Image Analysis

PET ligands and metabolic brain imaging Prof. Karl Herholz

Welcome and Introductions

A. General features of the basal ganglia, one of our 3 major motor control centers:

First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"

DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT

FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE

The PD You Don t See: Cognitive and Non-motor Symptoms

A. General features of the basal ganglia, one of our 3 major motor control centers:

symptoms of Parkinson s disease EXCEPT.

Behavioral Aspects of Parkinson s Disease

Assessment Toolkits for Lewy Body Dementia

Dementia Past, Present and Future

2/5/2015. Sensitive: Discriminative: Simple Inexpensive. Example of a good biomarker: blood tests, CSF test but they are not discriminative for PD

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit

Overview of neurological changes in Alzheimer s disease. Eric Karran

Multiple choice questions: ANSWERS

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information

The Person: Dementia Basics

Premotor PD: autonomic failure

Transcription:

La neurosonologia Nelle patologie degenerative e vascolari cerebrali Andrea Pilotto Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative Prof. Daniela Berg Department of Neurodegeneration Hertie Institut for Clinical Bain Research, DZNE German Center for Neurodeenerative disorders University of Tuebingen, Germany Prof. Alessandro Padovani Neurology Unit Department of Clinical and Experimental Sciences University of Brescia, Italy

Anatomy and method: the TCS TCS in differential diagnosis of parkinsonism TCS in dementia TCS in proprodromal disease stages New research directions

Anatomy and method: the transcranial ultrasound (TCS)

Advantages: Non-invasive Cheap Fast Mobile No effect with patient s head movements Unlimited repeatability Disadvantages: Needs expertise Depends on temporal bone window (10-15% no window) Different cut-off values with different machines and populations

Different planes Walter et al. Ultraschall Med 2014

Midbrain plane

Reduced echogenicity of the midbrain raphe 10 % of the normal population 50 70 % of patients with depressive disorders. Walter et al. Brain 2007

SN hyperechogenicity

SN hyperechogenicity evaluation Grading: Isoechogenic Mildly echogenic Hyperechogenic SN planimetric measurement 0.28 cm2

Control Parkinson s disease Prevalence in Parkinson s disease > 90% (Berg et al., 2001; Walter et al., 2002) Independent publications Sommer et al., 2004; Spiegel et al., 2006; Tromp et al., 2005; Ressner et al., 2005; Skoloudik et al., 2005; Zedde et al., 2005; Hagenah et al., 2006; Iova et al., 2005; Miranda et al., 2006 ; Wu et al., 2007; Behnke et al. 2009, Hellwig et al. 2014 Shu et al. 2014, Li et al., 2015,

Cut-offs should be calcolated for: SN Cut-off standardisation 1) Different machines 2) Different populations 100 Healthy adult subjects 90th percentile should represent the cut-off in the healthy population

TCS in differential diagnosis of Parkinsonism

Dementia Parkinsonism Apathy, depression Behavioral abnormlities Disinhibition Language impairment FTD CBS Asymmetric akinetic-rigid parkinsonism Limb apraxia, dystonia/myoclonus Cortical sensory loss, alien limb Eye movements abnormalities Gait disorder with falls Poor L-Dopa response Alzheimer s Disease PSP Memory impairment Cognitive decline DLB Parkinson s Disease MSA Autonomic involvement Cerebellar signs Poor L-dopa response Dementia + parkinosnism Cognitive fluctuation Hallucinations

Dementia Parkinsonism TDP- 43 FTD ALS CBS TAU Alzheimer s Disease PSP Alpha-synuclein DLB Parkinson s Disease MSA Amyloid

PSP

MSA

SN in differential diagnosis of tremor? Comparison 44 ET, 100 PD, 100 HC (Stockner et al. Mov Disord 2007) SN+: 8-10% of normal population 33% of ET SN+ SN in differential diagnosis of parkinsonism? SPS Walter et al. Neurology 2003 Walter et al. Arch Neurol 2007

Disease Substantia Nigra Raphe Ventricles Basal ganglia Sporadic PD - - Atypical PS - - 3. Ventricle PSP /- - - Metabolics - - Hydrocephalus - - - Essential Tremor ( ) - - - Pilotto et al. 2015

From parkinsonism to dementia.. Alzheimer s disease Parkinson s Dementia Dementia with Lewy bodies Frontotemporal dementia

The B/E ratio 2.5 separated two groups with a sensitivity of 83 % and a specificity of 76 %, with an area under the curve (AUC) of 0.81

SN and TCS in prodromal neurodegeneration about 8-10 % of healthy adults display increased echogenicity similar to Parkinson s disease

Is there any functional relevance of increased SN-echogenicity in healthy subjects? Association with signs of motor retardation in elderly people Berg et al., 2001, Behnke et al., 2007 Found in asymptomatic mutation carriers for monogenetic PD and associated with positive family history Walter, et al., 2003; Schweitzer et al., 2007 Relation of SN hyperechogenicity, olfactory dysfunction and SPECT abnormality Sommer et al., 2004, Haehner et al., 2007 Relation of SN hyperechogenicity and REM sleep behaviour disorder Unger et al., 2008

Berg et al. Neurology 1999; Arch Neurol 2002 Caudatus R Caudatus L Putamen R Putamen L Caudate R Caudate L Putamen R Putamen L 2.6 18 F-DOPA-Uptake 2.4 2.2 2.0 1.8 1.6 CO SN+ CO SN+ CO SN+ CO SN+

SN+ Up to 2006, development of PD had been observed in at least 14 healthy subjects with SN hyperechogenicity Khalia et al. Lancet Neurol 2015 Parkinson Premotor Prospective Studies - PRIPS Baseline assessment 1847 subjects 254 SN+ Berg et al. Arch Neurol 2011, Berg et al. Mov Disord 2013 8/10 PD patients SN+ 3 years: RR = 17.37 PPV = 3.1% 14/17 PD patients SN+ 5 years: RR = 20.6 PPV = 6.5%

SN hyperechogenicity hyposmia Depression and anxiety Autonomic dysfunction And constipation Dopaminergic dysfunction Rem behavioral disorders Prodromal PD symptoms and markers Visual alterations and cognitive impairment

Risk of prodromal PD Prodromal PD criteria calculation 100% 90% 50% 20% 10% 2% Male subject, 70 years old

Population-based study Enriched-cohort

Incident PD PD-free individuals SN hyperechogenicity the only marker associated with PD in both cohorts (p=0.004) Pilotto et al. 2017

Novel technologies in TCS and prodromal neurodegeneration

Prodromal neurodegeneration markers Subthreshold parkinsonism Imaging markers Ray Kennedy

Novel technologies and methods - active contour algorithms - 3D SN detection based (random forests vs principal component analyses) Skoloudik 2014 AJNR still dependent on: - image s quality - operator s skills

Novel technologies and methods Plate et al. Ultras Med 2012

Conclusions SN+ is present in 90% of PD patients TCS can be used in differential diagnosis of movement disorders TCS can be used for differential diagnosis of dementia TCS can identify prodromal neurodegeneration Advantages: Disadvantages: easy to apply quick to perform (dyskinetic, agitated) cheap dependent on investigator/ultrasound system insufficient bone window in about 10-15%

Prof. Alessandro Padovani Prof. Barbara Borroni Neurology Unit Department of Clinical and Experimental Sciences University of Brescia, Italy Prof. Daniela Berg Department of Neurodegeneration Hertie Institut for Clinical Bain Research, DZNE German Center for Neurodeenerative disorders University of Tuebingen, Germany